Erectile Dysfunction Clinical Trial
Official title:
A Prospective Randomized Study Whether Low-energy Extracorporeal Shockwave Therapy (LI-ESWT) Can Increase Erectile Function in Patients After Radical Prostatectomy
The purpose of this project is to verify the relationship between low intensity shock wave treatment (LI-SWT) and increased scores in self-assessment regarding to erectile function (ED) and sexual intercourse, in patients, who has undergone a radical prostatectomy (RP). The data will be obtained from patients using international accepted sexual questionnaires prior to the LI-SWT and 5, 12 and 24 weeks following treatment.
Extracorporeal shockwave therapy (ESWT) has been used for many years in different fields. In
1980, the clinical use of extracorporeal shockwave lithotripsy as a treatment for stone
disease in the upper urinary tract began and proved effective. Throughout the years, ESWT has
been modified for use in other specialties, such as in the treatment of gallstones,
sialolithiasis and Peyronie's disease. Animal studies have demonstrated neoangiogenesis in
myocardial tissue and skin flaps as well as regeneration of nervous tissue. Gotte et al.
found that shock waves can, under suitable conditions, lead to non-catalytic synthesis of
physiologically relevant quantities of NO. These pioneering findings corroborate our
hypothesis that ED due to RP, can likely be treated by LI-SWT.
It is well known that patients radically operated for prostate cancer subsequently develop
erectile dysfunction (ED) and /or urinary incontinence. A meta-analysis from 2009 found that
the overall erection recovery rate after prostatectomy were 58%, meaning that a certain
amount of patients still suffer from ED in the postoperative lifespan.
The investigators want to investigate in a randomized trial whether LI-ESWT is efficient in
ED patients, who has undergone RP, regarding to sexual function. These data will be assessed
by changes in outcome of sexual questionnaire regarding to sexual function and erection
hardness. This hypothesis has previous been tested in a Danish pilot study. The study design
was a prospective cohort study with 16 participants all suffering from ED due to nerve
sparing RD. The participants received two series of LI-ESWT per week in a 3-week period. The
results indicated a gradual increase in erectile function at the 1 month follow up, evaluated
by cross matching the IIEF-15 scores before and after treatment. However, the effect was
damped off at the last follow up one year later. The pilot study concluded that more research
had to be done in a larger population group.
The study design is decided to be a prospective, blinded, randomized placebo-control follow
up design. The total enrol of participants are estimated to be sixty-four divided into a
placebo group and an active group.
The participants who meet the inclusions criteria (see section below) will be randomly
assigned to either a control group (P) or an active group based (V) on a randomization list.
The treatment sessions will take place at the outpatient clinic of the department of urology
L, OUH. The shock wave device used for this study is a duolith® SD1 T-Top from Storz Medical
(see fig. 2). The device is set at 0.15 mJ/mm2, 5 Hz, with a total of 3000 impulses, and a
total energy of 12.8 J per treatment. LI-ESWT will be performed in six positions on the penis
(distal, center and proximal part of each cavernous body) and given by a therapist educated
for the purpose. The cap used to prevent LI-SWT in the placebo group will be positioned by
the Head of the Department to ensure valid blinding.
Prior to the treatment, the participants will be asked to fulfil questionnaires (EHS, IIEF-15
and DAN-PSS) to assess data on lower urinary tract symptoms, sexual dysfunction and erection
hardness. At the first treatment session (baseline function), the investigator reviews the
questionnaires in cooperation with the participant to ensure no conflicts and
misunderstanding in questions.
There will be a total of 5 treatment sessions during a 5-week period. Shortly after
treatment, the participants will be asked to fill in the questionnaires once again. The
questionnaires will be mailed to the participants home addresses together with a prepaid
return envelope and asked to be reposted at 5th, 12th and 24th week respectively.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05366504 -
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
|
Phase 2/Phase 3 | |
Recruiting |
NCT02573805 -
the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
Recruiting |
NCT02225548 -
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
|
Phase 4 | |
Completed |
NCT02587988 -
Trial to Evaluate the Efficacy and Safety of HCP1302
|
Phase 3 | |
Completed |
NCT02945462 -
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
|
Phase 1 | |
Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
Completed |
NCT01698684 -
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
|
Phase 4 | |
Not yet recruiting |
NCT01321489 -
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
|
Phase 3 | |
Completed |
NCT02226237 -
Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy
|
N/A | |
Terminated |
NCT01262833 -
Pudendal Assessment in Erectile Dysfunction
|
N/A | |
Completed |
NCT01230541 -
Effect of Udenafil on Spermatogenesis
|
Phase 1 | |
Completed |
NCT01037244 -
Treatment of Erectile Dysfunction I
|
Phase 3 | |
Completed |
NCT01037218 -
Treatment of Erectile Dysfunction II
|
Phase 3 | |
Recruiting |
NCT00313898 -
Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
|
Phase 4 | |
Completed |
NCT00663728 -
Assessment of Duration of Erection With Vardenafil 10 mg
|
Phase 4 | |
Completed |
NCT00667979 -
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
|
Phase 4 | |
Completed |
NCT00421083 -
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
|
Phase 3 |